Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, has scheduled its third quarter 2024 financial results release for November 12, 2024. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in information.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di una nuova terapia per il trattamento dell'Alzheimer, mirante a colpire gli oligomeri di beta amiloide solubili tossici, ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 per il 12 novembre 2024. L'azienda organizzerà una teleconferenza e una trasmissione audio in diretta alle 8:00 AM ET nello stesso giorno per discutere aggiornamenti aziendali e performance finanziaria. I partecipanti interessati devono registrarsi in anticipo almeno un giorno per ricevere le informazioni per la chiamata.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmacéutica en etapa clínica centrada en desarrollar una nueva terapia dirigida a los oligómeros de beta amiloide solubles tóxicos para el tratamiento del Alzheimer, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el 12 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia y una transmisión de audio en vivo a las 8:00 a.m. ET el mismo día para discutir actualizaciones comerciales y rendimiento financiero. Los participantes interesados deben registrarse con al menos un día de anticipación para recibir la información de acceso.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 독성 용해성 아밀로이드 베타 올리고머를 겨냥한 새로운 치료제를 개발하는 데 집중하는 임상 단계의 생명공학 회사로, 알츠하이머병 치료를 위해 2024년 3분기 재무 결과 발표를 2024년 11월 12일로 예정했습니다. 회사는 같은 날 오전 8시(ET)에 비즈니스 업데이트 및 재무 성과에 대해 논의하기 위한 전화 회의 및 오디오 웹캐스트를 개최할 것입니다. 관심 있는 참가자들은 전화 회의 정보를 받기 위해 최소 하루 전까지 사전 등록해야 합니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'une nouvelle thérapie ciblant les oligomères de bêta-amyloïde solubles toxiques pour le traitement de la maladie d'Alzheimer, a prévu la publication de ses résultats financiers du troisième trimestre 2024 pour le 12 novembre 2024. L'entreprise organisera un appel de conférence et un webinaire audio à 8h00, heure de l'Est, le même jour pour discuter des mises à jour commerciales et de la performance financière. Les participants intéressés doivent s'inscrire au moins un jour à l'avance pour recevoir les informations de connexion.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer neuen Therapie zur gezielten Behandlung von toxischen löslichen Amyloid-Beta-Oligomeren für die Behandlung von Alzheimer konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für den 12. November 2024 angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um Geschäftsaktualisierungen und die finanzielle Leistung zu diskutieren. Interessierte Teilnehmer müssen sich mindestens einen Tag im Voraus registrieren, um die Einwahlinformationen zu erhalten.
- None.
- None.
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) report Q3 2024 earnings?
What time is Acumen Pharmaceuticals (ABOS) Q3 2024 earnings call?
How can I access Acumen Pharmaceuticals (ABOS) Q3 2024 earnings call?
